Mainz Biomed presents data from pooled study at ASCO 2024

Mainz Biomed presented pivotal data from its largest cohort to date during a poster presentation at the American Society of Clinical Oncology 2024 Annual Meeting in Chicago, Illinois, and online. This data combines results from the ColoFuture and eAArly DETECT studies including additional patients collected since the first reported study results, demonstrating the significance of its innovative screening approach. The combined analysis involves 690 clinical subjects from 30 specialized gastroenterology centers across Europe and the United States, including previously unexamined and unreported samples, highlighting the remarkable efficacy of Mainz Biomed’s multimodal screening test. This test integrates the Fecal Immunochemical Test with proprietary mRNA biomarkers, complemented by an advanced AI and machine learning algorithm. This combination enables precise differentiation among colorectal cancer, advanced adenomas, non-advanced adenomas, and samples with no pathological findings. Key Findings Sensitivity for Colorectal Cancer: 92.3% Specificity: 90.1% Sensitivity for Advanced Precancerous Lesions: 82.2%; High-Grade Dysplasia Detection Rate: 95.8% This study highlighted the significant advantage of the multimodal screening test over existing methods, particularly in detecting advanced precancerous lesions. For example, the sensitivity for detecting high-grade dysplasia, which have an increased risk of turning into cancer, with the multimodal approach was 95.8%, significantly higher than other non-invasive tests currently available.